Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of HB0017 in Moderate to Severe Plaque Psoriasis
NCT05442788Phase 1Completed
- Sponsor
- Huabo Biopharm
- Start
- Sep 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HB0017 in plaque psoriasis (4 arms), sponsored by Huabo Biopharm. Primary endpoints: Incidence of treatment emergent adverse events and serious adverse events at 20 weeks, Elimination half-life at 20 weeks and 3 more. Started Sep 2021; status: completed.
02
Drugs
HB0017
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05442788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442788.